Table 1 Summary of patient information

From: Exploring drug resistance via intercellular crosstalk using spatial transcriptomics in high-grade serous ovarian carcinoma

ID

Age at diagnosis (years)

Diagnosis methods of ovarian cancer

FIGO stage

BRCA mutation

detected by WES

Treatment before sample collection

Age at sample collection (years)

Timing of sample collection

Sample

Histology

Treatment before olaparib treatment

Response to prior platinum regimen

Duration of olaparib maintenance therapy (months)

Treatment after olaparib

Outcome

S1

56

PDS

IIIC

Negative

None

56

PDS

Ovary

HGSOC

TC ×8

PR

7

TC ×4 →

Niraparib 9 months →

TC ×2 → PLD ×8 →

NGT ×1

AWD

S2

63

Ascites cytology

IVB

Not analyzed

(low quality)

TC ×8 → TC ×10 → PLD ×10 → NGT + Bev ×5 → NGT ×3 →

CDGP ×3 → CPT-11 ×1

68

Surgery for recurrence

Fallopian

tube

HGSOC

CPT-11 ×3 → TC ×6

CR

27

TC ×2

DOD

S3

48

Ascites cytology

IVA

Germline

TC ×5 +Bev ×3

49

IDS

Ovary

HGSOC

TC ×4 +Bev ×3 →

Bev maintenance ×10 →

TC + Bev ×9

CR

54

Ongoing

NED

S4

49

Exploratory laparotomy (BSO)

IIIB

Negative

TC ×6 → CmP/P ×3 →

TC ×2 → PLD ×4 →

TC ×3 → CDGP ×5 →

DTX ×3 → NGT ×7 → CPT-11 ×4

56

Surgery for recurrence

Vaginal

stump

HGSOC

CDGP ×6

PR

38

Onset of MDS followed by treatment for MDS

DOD

R1

38

PDS

IIIC

Negative

None

38

PDS

Ovary

HGSOC

TC ×6 → wPTX ×5 → PLD ×3 → PLD ×6 → CPT-11 ×2 → NGT ×2 →

GEM ×3 → CDGP + wPTX ×10 → CBDCA ×3

PR

2

CBDCA ×1

DOD

R2

52

Biopsy of abdominal wall metastasis

IVB

Negative

TC + Bev ×6 → TC ×7

53

IDS

Ovary

HGSOC

DC ×4 +Bev ×3 →

Bev maintenance ×11 →

Surgery → DC ×3

PR

4

PLD + Bev ×3 →

NGT + Bev ×3 →

GEM ×3

DOD

R3

77

Exploratory laparotomy (resection of peritoneal metastases)

IIIC

Negative

None

77

PDS

Peritoneum

HGSOC

TC ×8 → TC ×4 → TC ×8 →

PLD ×5 → GEM ×3 → DTX ×4 → wPTX ×8 → CPT-11 ×3 →

TC ×2 → GEM ×4 → CDGP ×3

PR

2

wPTX ×3 →

GEM ×3 →

CDGP ×8

DOD

R4

60

Ascites cytology

IIIC

Negative

TC ×6

60

IDS

Omentum

HGSOC

TC ×3

PR

3

PLD ×2 → NGT ×2

DOD

  1. PDS primary debulking surgery, IDS interval debulking surgery, TC paclitaxel + carboplatin, PLD pegylated liposomal doxorubicin, NGT nogitecan, Bev bevacizumab, CPT-11 irinotecan, CmP/P irinotecan + cisplatin, CDGP nedaplatin, wPTX weekly paclitaxel, DTX docetaxel, GEM gemcitabine, CBDCA carboplatin, DC docetaxel + carboplatin, PR partial response, CR complete response, AWD alive with disease, DOD died of disease, NED no evidence of disease, MDS myelodysplastic syndromes.